Volume 25, Issue 1 - Authors and Authorship

Attribution, advocacy, disposable authors, corporate ghosts and cultural assimilation: new themes in the ethical critique of commercial medical literature

Author: Alastair Matheson

Abstract

Download the full article

References

1. Huth EJ, Case K. The URM: twentyfive years old. Science Editor 2004; 27: 17-21.
2. Rennie D, Yank V, Emanuel L. When authorship fails. A proposal to make contributors accountable. JAMA 1997; 278: 579-585.
3. Rennie D. Integrity in scientific publishing. Health Serv Res 2010; 45: 885-896.
4. International Committee of Medical Journal Editors (ICMJE) Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (ICMJE Recommendations). Available from: http://www.icmje.org/recommendations/
5. Matheson A. Corporate science and the husbandry of scientific and medical knowledge by the pharmaceutical industry. BioSocieties 2008; 3: 355– 382.
6. Sismondo S. Key opinion leaders and the corruption of medical knowledge: what the Sunshine Act will and won’t cast light on. J Law Med Ethics. 2013;41:635-43.
7. Moynihan R. Key opinion leaders: independent experts or drug representatives in disguise? BMJ. 2008;336:1402-3.
8. White Paper: Key Opinion Leader Identification and Selection. A Pharma Matters Report. Thomson Reuters, January 2009. Available from: http://www.slideshare.net/driceman/kol-management?related=1
9. Matheson A. The disposable author: how pharmaceutical marketing is embraced within medicine’s scholarly literature. Hastings Center Report 2016; 10.1002/hast.576.
10. Wittek MR, Williams MJ, Carlson AM. Evidence development and publication planning: strategic process. Curr Med Res Opin. 2009;25:2723-7.
11. Sismondo S. Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry? PLoS Medicine 2007; 4: e286.
12. Battisti WP, Wager E, Baltzer L, Bridges D, Cairns A, Carswell CI, et al. Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3. Ann Intern Med. 2015;163:461-4.
13. Hoekman J, Frenken K, de Zeeuw D, Heerspink HL. The geographical distribution of leadership in globalized clinical trials. PLoS One 2012; 7: e45984.
14. Hirsch LJ. Conflicts of interest, authorship, and disclosures in industryrelated scientific publications: the tort bar and editorial oversight of medical journals. Mayo Clin Proc. 2009;84: 811-21.
15. Davidoff, F, C.D. DeAngelis, J.M. Drazen, M.G. Nicholls, J. Hoey et al. 2001. Sponsorship, authorship, and accountability. New England Journal of Medicine. 345:825-826.
16. DeAngelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. JAMA. 2004 Sep 15;292(11):1363-4
17. Lessig L. “Institutional corruption” defined. J Law Med Ethics 2013; 41: 2-4.
18. Foucault, M. (1980). The confession of the flesh. In M. Foucault (C. Gordon, Ed.), Power/knowledge: Selected interviews and other writings, 194–228. Brighton: Harvester Press.P 195.
19. Horton R. The Dawn of McScience. New York Review of Books. March 11 2004.
20. Drazen JM. Revisiting the commercialacademic interface. N Engl J Med 2014;372;19:1853-4.